An Open Label, Multicenter, Safety and Efficacy Phase II/III Study of PRL3-Zumab in Solid Tumors Patients (PRL-3-Zumab)
Solid Tumor
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
IBTISAM MUHAMAD NOR
CONTACT
SC: Nurshahida Binti Mohd Nawi
Beacon Hospital Sdn Bhd
PRINCIPAL INVESTIGATOR
Dr Tho Lye Mun
tholm@beaconhospital.com.my
03-77860846
A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician’s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal JunctionvvAdenocarcinoma, and Esophageal Adenocarcinoma) (TroFuse-010)
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
Dr. Malwinder Singh Sandhu
CONTACT
General Line: 03 – 2296 0888
CRC: 03-22960888 Ext.1320, 1321, 1322
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Dr David Lee Dai Wee/ Cryst
CONTACT
03-79492120
Sarawak General Hospital (SGH)
PRINCIPAL INVESTIGATOR
Dr. Eng Jie Yi/ Wee Wee Binti Buyong
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com, crcsghkuching@gmail.com (Email)
CLICK HERE (Facebook)
Hospital Pulau Pinang (HPP)
PRINCIPAL INVESTIGATOR
Dr. Tan Ai Lian/ Nur Shaphira Sholikin
CONTACT
+604-2225766/ +604-2225503
Institute Kanser Negara (IKN)
PRINCIPAL INVESTIGATOR
Dr. Norhidayu Salimin/ Hidayati Mohd Sha’ari
CONTACT
General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 5418 (Tel)
03-8892 5622 (Fax)
Pantai Hospital Kuala Lumpur (PHKL)
PRINCIPAL INVESTIGATOR
Dr. Malwinder Singh Sandhu/ Irfan Fikri Bin Badrul Hisham
CONTACT
General Line: 03 – 2296 0888
CRC: 03 – 2280 1320 / 2280 1321 / 2280 1322
An Open Label, Multicenter Safety and Efficacy Phase II/III Study of PRL3-Zumab in Solid Tumors Patients
Solid tumor
Beacon Hospital Sdn Bhd
PRINCIPAL INVESTIGATOR
Dr Tho Lye Mun
Contact: 03-77872830
tholm@beaconhospital.com.my
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Prof Dr Ho Gwo Fuang
CONTACT
SC: Madihah/ Toh Yok Yong
Contact: 03-79492120
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
IBTISAM MUHAMAD NOR
CONTACT
SC: Nurshahida Binti Mohd Nawi
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRAS G12C Mutant Solid Tumors
Solid tumor
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
VOON PEI JYE
CONTACT
Fong Yian Ching
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors (2023825-12801)
Solid tumor
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Assoc Prof Dr Wan Zamaniah Wan Ishak
CONTACT
SC: Suganiya (03-79492120)
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY PT-01)
For pancreas 1st line and gastric 2-3rd line
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Prof Ho/Prof Wan
CONTACT
SC: Wei Ying
03-79492120